相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anthracycline-Induced Cardiomyopathy Clinical Relevance and Response to Pharmacologic Therapy
Daniela Cardinale et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Adriana Albini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic-Pharmacodynamic Evaluation of Sunitinib
Carlo L. Bello et al.
CLINICAL CANCER RESEARCH (2009)
Fluoropyrimidine-associated cardiotoxicity: revisited
M. Wasif Saif et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cardiovascular toxicity caused by cancer treatment: strategies for early detection
Renske Altena et al.
LANCET ONCOLOGY (2009)
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Edith A. Perez et al.
MAYO CLINIC PROCEEDINGS (2009)
QT interval prolongation among patients treated with angiogenesis inhibitors
Stephane Ederhy et al.
TARGETED ONCOLOGY (2009)
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Constantine S. Tam et al.
BLOOD (2008)
Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition
Hai Ying Fu et al.
CARDIOVASCULAR RESEARCH (2008)
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
Ming Hui Chen et al.
CIRCULATION (2008)
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
Yun Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy
Aarif Y. Khakoo et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Ariel Fernandez et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Molecularly targeted oncology therapeutics and prolongation of the QT interval
Elizabeth L. Strevel et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
Daniela Cardinale et al.
CIRCULATION (2006)
Anthracycline cardiotoxicity
Robin L. Jones et al.
EXPERT OPINION ON DRUG SAFETY (2006)
Chronic health conditions in adult survivors of childhood cancer
Kevin C. Oeffinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity
Patrick C. H. Hsieh et al.
CIRCULATION (2006)
Neuregulin activates erbB2-dependent Src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes
Yukio Kuramochi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
Richard L. Piekarz et al.
CLINICAL CANCER RESEARCH (2006)
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs
Robin L. Jones et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP
MB Potts et al.
JOURNAL OF CELL BIOLOGY (2005)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
E Tan-Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiornyocytes - Implications for herceptin-induced cardiomyopathy
LP Grazette et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer
MM Cooney et al.
CLINICAL CANCER RESEARCH (2004)
Bevacizumab, bleeding, thrombosis, and warfarin
S Kilickap et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology
LM Schuchter et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cardiac dysfunction in the trastuzumab clinical trials experience
A Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
